Un-audited financial results for the quarter and half year ended as on 30th September, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts less than Nifty Microcap 250 and 1.2 pts less than its Diversified Commercial Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Johnson Pharmacare Limited reported nil revenue from operations for Q2 FY26 and the half year ended September 30, 2025, with total income at zero. The company posted a loss after tax of Rs. 0.34 lakh in Q2 FY26 versus a Rs. 5.34 lakh loss in Q2 FY25, and a Rs. 5.68 lakh loss for H1 FY26 versus Rs. 4.07 lakh in H1 FY25. Employee and other expenses remained minimal at under Rs. 6 lakhs for the half year. The balance sheet shows total assets of Rs. 5,836.76 lakhs, mostly held as investments of Rs. 4,229.16 lakhs and loans given of Rs. 1,469.50 lakhs, with equity of Rs. 5,611.24 lakhs and negligible borrowings. Net operating cash flow was positive at Rs. 48.33 lakhs for H1 FY26, supported by Rs. 50 lakhs raised from long-term borrowings.
The company continues to operate without any business revenue and is posting small recurring losses, indicating it functions more as a holdco with investments and loans rather than an active operating business. Shareholders should note the persistent absence of operational income, though asset base remains intact and losses are marginal relative to equity.